PON1 is a longevity gene: Results of a meta-analysis

Ageing Research Reviews

Volumn 8, Issue 4, 2009, Pages 277-284

  Lescai, Francesco ^a,b   Marchegiani, Francesca ^c   Franceschi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^c INRCA   (Italy)

Author keywords

Genetics; Longevity; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

AGING; CARDIOVASCULAR DISEASE; CODON; DNA POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; ITALY; LONGEVITY; POPULATION GENETICS; SHORT SURVEY;

AGED, 80 AND OVER; AGING; ARYLDIALKYLPHOSPHATASE; GENOTYPE; HUMANS; LONGEVITY; POLYMORPHISM, GENETIC;

EID: 69049095976     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2009.04.001     Document Type: Short Survey

References (91)

1. Adkins S., Gan K.N., Mody M., and LA Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52 (1993) 598-608
2. Akhmedova S.N., Yakimovsky A.K., and Schwartz E.I. Paraoxonase 1 Met--Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184 (2001) 179-182
3. Ausejo M., Saenz A., Pham B., Moher D., Chalmers T.C., Kellner J.D., Johnson D.W., and Klassen T.P. The effectiveness of glucocorticoids in treating croup: meta-analysis. West J. Med. 171 (1999) 227-232
4. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., and La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1617-1624
5. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., and La Du B. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 (1999) 892-904
6. Barbieri M., Bonafe M., Marfella R., Ragno E., Giugliano D., Franceschi C., and Paolisso G. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J. Clin. Endocrinol. Metab. 87 (2002) 222-225
7. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., and Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Jama 299 (2008) 1265-1276
8. Blatter Garin M.C., Abbott C., Messmer S., Mackness M., Durrington P., Pometta D., and James R.W. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem. J. 304 Pt 2 (1994) 549-554
9. Bonafe M., Marchegiani F., Cardelli M., Olivieri F., Cavallone L., Giovagnetti S., Pieri C., Marra M., Antonicelli R., Troiano L., Gueresi P., Passeri G., Berardelli M., Paolisso G., Barbieri M., Tesei S., Lisa R., De Benedictis G., and Franceschi C. Genetic analysis of Paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur. J. Hum. Genet. 10 (2002) 292-296
10. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., and Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001) 77-84
11. Bub A., Barth S., Watzl B., Briviba K., Herbert B.M., Luhrmann P.M., Neuhauser-Berthold M., and Rechkemmer G. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet. Eur. J. Nutr. 41 (2002) 237-243
12. Campo S., Sardo M.A., Trimarchi G., Bonaiuto M., Fontana L., Castaldo M., Bonaiuto A., Saitta C., Bitto A., Manduca B., Riggio S., and Saitta A. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp. Gerontol. 39 (2004) 1089-1094
13. Capri M., Salvioli S., Sevini F., Valensin S., Celani L., Monti D., Pawelec G., De Benedictis G., Gonos E.S., and Franceschi C. The genetics of human longevity. Ann. N. Y. Acad. Sci. 1067 (2006) 252-263
14. Capri M., Salvioli S., Monti D., Caruso C., Candore G., Vasto S., Olivieri F., Marchegiani F., Sansoni P., Baggio G., Mari D., Passarino G., De Benedictis G., and Franceschi C. Human longevity within an evolutionary perspective: the peculiar paradigm of a post-reproductive genetics. Exp. Gerontol. 43 (2008) 53-60
15. Catano H.C., Cueva J.L., Cardenas A.M., Izaguirre V., Zavaleta A.I., Carranza E., and Hernandez A.F. Distribution of paraoxonase-1 gene polymorphisms and enzyme activity in a Peruvian population. Environ. Mol. Mutagen 47 (2006) 699-706
16. Cherki M., Berrougui H., Isabelle M., Cloutier M., Koumbadinga G.A., and Khalil A. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp. Gerontol. 42 (2007) 815-824
17. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat. Med. 19 (2000) 3127-3131
18. Christiansen L., Bathum L., Frederiksen H., and Christensen K. Paraoxonase 1 polymorphisms and survival. Eur. J. Hum. Genet. 12 (2004) 843-847
19. Clendenning J.B., Humbert R., Green E.D., Wood C., Traver D., and Furlong C.E. Structural organization of the human PON1 gene. Genomics 35 (1996) 586-589
20. Dantoine T.F., Drouet M., Debord J., Merle L., Cogne M., and Charmes J.P. Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease. Ann. N.Y. Acad. Sci. 977 (2002) 239-244
21. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 (1996) 334-336
22. De Benedictis G., and Franceschi C. The genetics of successful aging. Aging (Milano) 10 (1998) 147-148
23. De Benedictis G., and Franceschi C. The unusual genetics of human longevity. Sci. Aging Knowledge Environ. (2006) pe20
24. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., and James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277 (2002) 4301-4308
25. Deakin S., Leviev I., Guernier S., and James R.W. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2083-2089
26. Deakin S., Moren X., and James R.W. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1146-1152
27. Deakin S.P., and James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. (Lond.) 107 (2004) 435-447
28. Depp C.A., and Jeste D.V. Definitions and predictors of successful aging: a comprehensive review of larger quantitative studies. Am. J. Geriatr. Psychiatry 14 (2006) 6-20
29. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin. Trials 7 (1986) 177-188
30. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
31. Ferre N., Camps J., Fernandez-Ballart J., Arija V., Murphy M.M., Ceruelo S., Biarnes E., Vilella E., Tous M., and Joven J. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin. Chem. 49 (2003) 1491-1497
32. Fleiss J.L. The statistical basis of meta-analysis. Stat. Methods Med. Res. 2 (1993) 121-145
33. Florentin M., Liberopoulos E.N., Wierzbicki A.S., and Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr. Opin. Cardiol. 23 (2008) 370-378
34. Franceschi C., Bonafe M., Valensin S., Olivieri F., De Luca M., Ottaviani E., and De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N.Y. Acad. Sci. 908 (2000) 244-254
35. Franceschi C., Olivieri F., Marchegiani F., Cardelli M., Cavallone L., Capri M., Salvioli S., Valensin S., De Benedictis G., Di Iorio A., Caruso C., Paolisso G., and Monti D. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech. Ageing Dev. 126 (2005) 351-361
36. Franceschi C., Bezrukov V., Blanche H., Bolund L., Christensen K., de Benedictis G., Deiana L., Gonos E., Hervonen A., Yang H., Jeune B., Kirkwood T.B., Kristensen P., Leon A., Pelicci P.G., Peltonen L., Poulain M., Rea I.M., Remacle J., Robine J.M., Schreiber S., Sikora E., Slagboom P.E., Spazzafumo L., Stazi M.A., Toussaint O., and Vaupel J.W. Genetics of healthy aging in Europe: the EU-integrated project GEHA (GEnetics of Healthy Aging). Ann. N.Y. Acad. Sci. 1100 (2007) 21-45
37. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., and Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99 (1997) 62-66
38. Glatt S.J., Chayavichitsilp P., Depp C., Schork N.J., and Jeste D.V. Successful aging: from phenotype to genotype. Biol. Psychiatry 62 (2007) 282-293
39. Harel M., Aharoni A., Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Sussman J.L., and Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419
40. He X.M., Zhang Z.X., Zhang J.W., Zhou Y.T., Tang M.N., Wu C.B., and Hong Z. Gln192Arg polymorphism in paraoxonase 1 gene is associated with Alzheimer disease in a Chinese Han ethnic population. Chin. Med. J. (Engl.) 119 (2006) 1204-1209
41. Hedges L.V., and Pigott T.D. The power of statistical tests in meta-analysis. Psychol. Methods 6 (2001) 203-217
42. Heijmans B.T., Westendorp R.G., Lagaay A.M., Knook D.L., Kluft C., and Slagboom P.E. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149 (2000) 91-97
43. James R.W., Blatter Garin M.C., Calabresi L., Miccoli R., von Eckardstein A., Tilly-Kiesi M., Taskinen M.R., Assmann G., and Franceschini G. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis 139 (1998) 77-82
44. Jaouad L., Milochevitch C., and Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic. Res. 37 (2003) 77-83
45. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
46. Kondo I., and Yamamoto M. Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res. 806 (1998) 271-273
47. Lawlor D.A., Day I.N., Gaunt T.R., Hinks L.J., Briggs P.J., Kiessling M., Timpson N., Smith G.D., and Ebrahim S. The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis. BMC Genet. 5 (2004) 17
48. Letellier C., Durou M.R., Jouanolle A.M., Le Gall J.Y., Poirier J.Y., and Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab. 28 (2002) 297-304
49. Leus F.R., Wittekoek M.E., Prins J., Kastelein J.J., and Voorbij H.A. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149 (2000) 371-377
50. Leviev I., Negro F., and James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2935-2939
51. Leviev I., Deakin S., and James R.W. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J. Lipid Res. 42 (2001) 528-535
52. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122 (1997) 265-268
53. MacKness B., Mackness M.I., Durrington P.N., Arrol S., Evans A.E., McMaster D., Ferrieres J., Ruidavets J.B., Williams N.R., and Howard A.N. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur. J. Clin. Invest. 30 (2000) 4-10
54. Mackness B., Durrington P.N., Boulton A.J., Hine D., and Mackness M.I. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur. J. Clin. Invest. 32 (2002) 259-264
55. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
56. Mackness M.I., and Durrington P.N. Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet 346 (1995) 856
57. Malin R., Jarvinen O., Sisto T., Koivula T., and Lehtimaki T. Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis. Atherosclerosis 157 (2001) 301-307
58. Malin R., Loimaala A., Nenonen A., Mercuri M., Vuori I., Pasanen M., Oja P., Bond G., Koivula T., and Lehtimaki T. Relationship between high-density lipoprotein paraoxonase gene M/L55 polymorphism and carotid atherosclerosis differs in smoking and nonsmoking men. Metabolism 50 (2001) 1095-1101
59. Marchegiani F., Marra M., Spazzafumo L., James R.W., Boemi M., Olivieri F., Cardelli M., Cavallone L., Bonfigli A.R., and Franceschi C. Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci. 61 (2006) 541-546
60. Marchegiani F., Marra M., Olivieri F., Cardelli M., James R.W., Boemi M., and Franceschi C. Paraoxonase 1: genetics and activities during aging. Rejuvenation Res. 11 (2008) 113-127
61. Mariani L., Turchetti G., and Franceschi C. Chronic antigenic stress, immunosenescence and human survivorship over the 3 last centuries: heuristic value of a mathematical model. Mech. Ageing Dev. 124 (2003) 453-458
62. Marra M., Marchegiani F., Antonicelli R., Sirolla C., Spazzafumo L., Olivieri F., Franceschi C., Testa R., Paolisso G., James R.W., Boemi M., and Parati G. The PON1192RR genotype is associated with a higher prevalence of arterial hypertension. J. Hypertens. 24 (2006) 1293-1298
63. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
64. Muncer S., Taylor S., and Craigie M. Power dressing and meta-analysis: incorporating power analysis into meta-analysis. J. Adv. Nurs. 38 (2002) 274-280
65. Murata M., Maruyama T., Suzuki Y., Saruta T., and Ikeda Y. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet. Med. 21 (2004) 837-844
66. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., Reddy S., Shih D., Shi W., Watson A.D., Van Lenten B.J., Vora D., and Fogelman A.M. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 481-488
67. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., and Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic. Biol. Med. 41 (2006) 1031-1040
68. Novelli V., Viviani Anselmi C., Roncarati R., Guffanti G., Malovini A., Piluso G., and Puca A.A. Lack of replication of genetic associations with human longevity. Biogerontology 9 (2008) 85-92
69. Ottaviani E., and Franceschi C. A new theory on the common evolutionary origin of natural immunity, inflammation and stress response: the invertebrate phagocytic immunocyte as an eye-witness. Domest. Anim. Endocrinol. 15 (1998) 291-296
70. Pauk V.V., Tuktarova I.A., Nasibullin T.R., Zueva L.P., Adel'guzhina A., Khusnutdinova E.K., and Mustafina O.E. [Paraoxonase 1 gene polymorphism 192Q/R in old men and long-livers from Tatars ethnic group]. Mol Biol. (Mosk) 41 (2007) 601-607
71. Pfohl M., Koch M., Enderle M.D., Kuhn R., Fullhase J., Karsch K.R., and Haring H.U. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48 (1999) 623-627
72. Poh R., and Muniandy S. Ethnic variations in paraoxonase1 polymorphism in the Malaysian population. Southeast Asian J. Trop. Med. Public Health 38 (2007) 392-397
73. Rea I.M., McKeown P.P., McMaster D., Young I.S., Patterson C., Savage M.J., Belton C., Marchegiani F., Olivieri F., Bonafe M., and Franceschi C. Paraoxonase polymorphisms PON1 192 and 55 and longevity in Italian centenarians and Irish nonagenarians. A pooled analysis. Exp. Gerontol. 39 (2004) 629-635
74. Robertson K.S., Hawe E., Miller G.J., Talmud P.J., and Humphries S.E. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim. Biophys. Acta 1639 (2003) 203-212
75. Rosenblat M., Gaidukov L., Khersonsky O., Vaya J., Oren R., Tawfik D.S., and Aviram M. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281 (2006) 7657-7665
76. Rozek L.S., Hatsukami T.S., Richter R.J., Ranchalis J., Nakayama K., McKinstry L.A., Gortner D.A., Boyko E., Schellenberg G.D., Furlong C.E., and Jarvik G.P. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J. Lipid Res. 46 (2005) 1888-1895
77. Salvioli S., Capri M., Valensin S., Tieri P., Monti D., Ottaviani E., and Franceschi C. Inflamm-aging, cytokines and aging: state of the art, new hypotheses on the role of mitochondria and new perspectives from systems biology. Curr. Pharm. Des. 12 (2006) 3161-3171
78. Schmidt H., Schmidt R., Niederkorn K., Gradert A., Schumacher M., Watzinger N., Hartung H.P., and Kostner G.M. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 29 (1998) 2043-2048
79. Senti M., Tomas M., Vila J., Marrugat J., Elosua R., Sala J., and Masia R. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis 156 (2001) 443-449
80. Senti M., Tomas M., Fito M., Weinbrenner T., Covas M.I., Sala J., Masia R., and Marrugat J. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 88 (2003) 5422-5426
81. Seres I., Paragh G., Deschene E., Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Gerontol. 39 (2004) 59-66
82. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
83. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L., and Lusis A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275 (2000) 17527-17535
84. Sorenson R.C., Primo-Parmo S.L., Kuo C.L., Adkins S., Lockridge O., and La Du B.N. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 7187-7191
85. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., and Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
86. Van Lenten B.J., Reddy S.T., Navab M., and Fogelman A.M. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb. Vasc. Biol. 26 (2006) 1687-1688
87. Voetsch B., Benke K.S., Damasceno B.P., Siqueira L.H., and Loscalzo J. Paraoxonase 192 Gln-->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33 (2002) 1459-1464
88. Wang X., Fan Z., Huang J., Su S., Yu Q., Zhao J., Hui R., Yao Z., Shen Y., Qiang B., and Gu D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb. Vasc. Biol. 23 (2003) 328-334
89. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., and Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
90. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
91. Zubenko G.S., Stiffler J.S., Hughes III H.B., Fatigati M.J., and Zubenko W.N. Genome survey for loci that influence successful aging: sample characterization, method validation, and initial results for the Y chromosome. Am. J. Geriatr. Psychiatry 10 (2002) 619-630